By in

Sativa agrees purchase of 100% of CBD product provider George Botanicals

Press Release                                                                                                              Friday 22 June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa agrees purchase of 100% of CBD product provider George Botanicals 

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has agreed to purchase, for £415,000, 100 per cent of George Botanicals Ltd, a UK-based manufacturer, wholesaler and distributor of wellness CBD products, following the Memorandum of Understanding announced by Sativa on Tuesday 17 April, 2018. The Company will pay £215,000 in cash and £200,000 in shares in Sativa at £0.04 per share.

The vendor is Carbon Managers Limited (“Carbon Managers”), of which Sativa’s Chief Executive Officer, Geremy Thomas, is the 100 per cent shareholder. Geremy Thomas and George Thomas are significant shareholders in Sativa and both are also Directors of Carbon Managers. Pursuant to the NEX Exchange Growth Market Rules for Issuers, the transaction would therefore constitute a related party transaction. Geremy Thomas is not involved in any of Sativa’s decision-making process in relation to this purchase.   

Mark Blower, Executive Director of Sativa Investments, said: “There are 365,000 confirmed users of CBD oil in the UK today and the market over the next two years will be worth £100 million, according to the Cannabis Trades Association. George Botanicals is well-placed to gain a significant market share.”

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.   

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

By in

Sativa passes resolution at General Meeting to broaden investment policy

Press Release                                                                                                              Friday 22 June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa passes resolution at General Meeting to broaden investment policyto meet widening global demand for medicinal cannabis

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, announces that all Resolutions were passed by the requisite majority at the Company’s General Meeting today, including Resolutions to broaden its investment strategy beyond Canada, the authority to allot shares, and the disapplication of pre-emption rights.

Since listing on the NEX Exchange Growth Market on Thursday 29th March 2018, Sativa has pursued numerous potential investments and has already announced that it has completed two investments, these being in Veritas Pharma Inc. and Rapid Dose Therapeutics Inc. on 21 May and 23 May respectively. This week, the Company appointed pharmacologist Sir Alasdair Breckenridge, to its already heavyweight Advisory Board, to assist Sativa in navigating its way in the sector and advise on investments ahead of anticipated regulatory change in Europe, including the UK.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “Since Sativa’s listing, the market has had a governmental and societal sea change of attitudes to medicinal cannabis. In the past two weeks, the UK has seen the two high profile cases of Alfie Dingley and Billy Caldwell, two young boys who suffer from rare forms of epilepsy and need medicinal cannabis for their treatment, which was initially rejected to them by the UK authorities, generating widespread consternation and condemnation. In both cases, the Home Secretary then intervened and issued a licence from the Home Office.

“It is hard to see how the UK’s stance and that of a few other leading EU countries, which are also resisting medicinal advanced therapy, can continue without accepting that the controlled use of medicinal cannabis has an important part to play in healthcare.”

The Directors of the Company accept responsibility for the contents of this announcement.

 

– Ends  –

 

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

By in

Sativa Share Price Movement

Press Release                                                                                                              Friday 22 June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

(“Sativa” or “the Company”) 

Sativa share price movement

The Board of Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, notes the recent rise in the Company’s share price.

Whilst the Company has made investments to date, it is unaware of any specific reason for this recent movement.

The Board notes the significant increase in media and investor interest in the medical cannabis market, including the statement by the UK Home Secretary earlier this week highlighting the potential legalisation of cannabis for medicinal use in this country. As the UK’s only quoted medicinal cannabis company, the Board believes that Sativa is increasingly being viewed by the UK investment community as the de-facto UK investment vehicle for the sector, leading to the recent share price strength and enhanced demand for the Company’s shares.

Sativa would like to draw investor attention to the Company’s Admission Document, wherein Subscribers who participated in the Subscription at IPO undertook with the Company and Peterhouse, the Company’s Corporate Adviser and Broker, not to dispose of any interest in the Ordinary Shares held by them for a period of 12 months following Admission, which took place on 29 March 2018, in such manner as may reasonably be required without first consulting the Company and Peterhouse in order to maintain an orderly market in the Subscription Shares.

The Directors of the Company accept responsibility for the contents of this announcement.

– Ends  –

 

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/